Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or new human data
PubMed 37833948 · doi:10.3390/ijms241914499
What was done
This narrative review summarizes findings from preclinical research and clinical trials targeting beta-amyloid in Alzheimer's disease, focusing on phase III trials of aducanumab, lecanemab, and donanemab, as well as physiological roles of amyloid-beta.
What was found
No quantitative data or effect sizes are reported in the abstract. The author reports that while anti-amyloid therapies markedly lower brain beta-amyloid load in phase III trials, they demonstrate limited efficacy on cognitive parameters, and preclinical evidence indicates beta-amyloid has physiological functions including memory formation.
Why it matters
It synthesizes the clinical disconnect between target engagement (amyloid clearance) and clinical benefit, arguing that Alzheimer's disease is multifactorial and that focusing solely on amyloid clearance may be insufficient.
Limits
The abstract contains no quantitative metrics, search strategy, or sample sizes. As a narrative review rather than a systematic review or meta-analysis, it provides qualitative interpretation rather than formal pooled evidence.
Cited by
- context Accumulation of beta-amyloid in the brain is not the cause of Alzheimer's disease.